<h4>Background</h4>Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targetable hormone receptors, making conventional chemotherapy the primary treatment option, despite its associated toxicity and potential for drug resistance. This evidence concerns the gene NR4A1 and triple-negative breast carcinoma.